Bridged Bicyclo Compounds, Heterocyclic
"Bridged Bicyclo Compounds, Heterocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common.
| Descriptor ID |
D019086
|
| MeSH Number(s) |
D03.605.084
|
| Concept/Terms |
Bridged Bicyclo Compounds, Heterocyclic- Bridged Bicyclo Compounds, Heterocyclic
- Bicyclo Compounds, Heterocyclic
- Heterocyclic Bicyclo Compounds
- Bicyclic Heterocyclic Compounds
- Heterocyclic Compounds, Bicyclic
- Heterocyclic Cpds, Bicyclic
- Bicyclic Heterocyclic Cpds
|
Below are MeSH descriptors whose meaning is more general than "Bridged Bicyclo Compounds, Heterocyclic".
Below are MeSH descriptors whose meaning is more specific than "Bridged Bicyclo Compounds, Heterocyclic".
This graph shows the total number of publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in this website by year, and whether "Bridged Bicyclo Compounds, Heterocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 6 | 1 | 7 |
| 2025 | 2 | 6 | 8 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Sep; 44(25):2422-2434.
-
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.
-
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04; 394(21):2107-2116.
-
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. Signal Transduct Target Ther. 2026 Apr 27; 11(1).
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026 01 15; 147(3):276-289.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 11; 39(11):2697-2707.
-
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868.
-
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.
-
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica. 2026 01 01; 111(1):158-167.
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 08 10; 43(23):2606-2615.